Quviviq (daridorexant) is a medication used to treat insomnia [1]. Information regarding the synthesis patent for Quviviq is not readily available in the provided context. Patent information for pharmaceuticals is complex and can involve multiple patents covering the active ingredient, manufacturing processes, and specific formulations.
When does Quviviq's patent expire?
The expiration date of Quviviq's patent is not specified in the provided information. Pharmaceutical patent cliffs, the point at which patent protection ends and generic competition can begin, are crucial for market dynamics. DrugPatentWatch.com tracks and provides information on pharmaceutical patent expirations [2].
Who makes Quviviq?
Quviviq is developed and marketed by Idorsia Pharmaceuticals [1].
What is Quviviq used for?
Quviviq is prescribed for the treatment of insomnia in adults, characterized by difficulty with sleep onset or sleep maintenance [1].
How does Quviviq work?
Quviviq is a dual orexin receptor antagonist. It works by blocking the wake-promoting actions of orexin neuropeptides in the brain, thereby reducing sleep-wakefulness and promoting sleep [1].
What are the potential side effects of Quviviq?
Common side effects reported for Quviviq include somnolence, headache, and fatigue [1].
Are there alternatives to Quviviq for insomnia?
Other medications for insomnia exist, including benzodiazepines, non-benzodiazepine hypnotics (Z-drugs), melatonin receptor agonists, and certain antidepressants used off-label. Quviviq's mechanism of action as a dual orexin receptor antagonist distinguishes it from many of these other options.
Can generic versions of Quviviq be developed?
Once Quviviq's relevant patents expire and any other market exclusivities conclude, generic manufacturers can apply to produce and market generic versions of the drug. The process for generic drug approval involves demonstrating bioequivalence to the reference listed drug.
Sources:
[1] https://www.drugpatentwatch.com/drug/quviviq
[2] https://www.drugpatentwatch.com/